19 recruiting, 15 not yet recruiting, 14 unknown, 10 completed. 65 Phase 3, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 65 | Recruiting 19, Not yet recruiting 15, Unknown 14, Completed 10, Active not recruiting 5, Terminated 2 |
| Phase 2 | 16 | Unknown 6, Not yet recruiting 5, Recruiting 3, Completed 2 |
Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 500 | 2026-11-25 | 2026-11-04 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer | Phase 3 | Not yet recruiting | Fudan University | 394 | 2026-11-15 | 2026-11-12 |
| ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 600 | 2026-10-20 | 2026-11-16 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ QLS31905, Sintilimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 560 | 2026-09-24 | 2026-10-19 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-09-08 | 2026-11-09 |
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases Retlirafusp alfa Injection, Capecitabine, Oxaliplatin - Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 3 | Not yet recruiting | Peking University | 332 | 2026-06-26 | 2026-06-30 |
| Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer Sintilimab, Lenvatinib, Comprehensive Local Consolidative Therapy - Hepatocellular Carcinoma (HCC), Metastases | Phase 3 | Not yet recruiting | Tongji Hospital | 400 | 2026-05-30 | 2026-04-17 |
| A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. Bevacizumab, Capecitabine, Oxaliplatin - Hepatocellular Carcinoma (HCC) | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 680 | 2026-03-27 | 2026-04-16 |
| Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab - Anal Squamous Cell Carcinoma, Limited-stage | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 350 | 2026-03-17 | 2026-07-09 |
| Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PD1 antibody, Medroxyprogesterone Acetate 500 MG, Megestrol Acetate 160 MG - Endometrial Cancer, Fertility | Phase 2 / Phase 3 | Recruiting | Fudan University | 260 | 2026-01-25 | 2026-03-13 |
| Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma Sintilimab plus nab-paclitaxel and platinum-based chemotherapy, Radical surgery combined with radiotherapy or chemoradiotherapy - Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC) | Phase 3 | Recruiting | Qunxing Li,MD | 104 | 2026-01-01 | 2026-01-28 |
| Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC Sintilimab, radiotherapy, TACE - Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 286 | 2025-07-10 | 2025-09-22 |
| Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy - Gastric Neoplasm | Phase 2 / Phase 3 | Not yet recruiting | Queling Liu | 30 | 2025-06-01 | 2025-05-16 |
| PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma Sintilimab, Capecitabine - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 664 | 2025-05-01 | 2025-04-02 |
| Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX - Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy | Phase 3 | Recruiting | Zuoyi Jiao | 682 | 2025-04-15 | 2025-04-22 |
Showing 20 of 65. Sign in to see all of them.
Carcinoma, Hepatocellular (12) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Esophageal Neoplasms (4) · Esophageal Squamous Cell Carcinoma (4) · Endometrial Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anus Neoplasms (1) · Carcinoma, Squamous Cell (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Hepatoblastoma (1) · Liver Neoplasms (1)
Innovent Biologics (Suzhou) Co. Ltd. (14) · Sun Yat-sen University (6) · Tongji Hospital (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Fudan University (2) · Hutchmed (2) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Yao Hongwei (2) · Beijing Friendship Hospital (1) · Changzhou Cancer Hospital of Soochow University (1) · Chinese Academy of Medical Sciences (1) · Chipscreen Biosciences, Ltd. (1) · First Affiliated Hospital Xi'an Jiaotong University (1)
China (59) · Australia (1) · Belgium (1) · France (1) · Hungary (1) · Spain (1) · United States (1)
Caicun Zhou (1) · Chen Li, PhD (1) · Degan Lu, professor (1) · Dingwei Ye (1) · Hao Feng (1) · Jason Wu (1) · Jia Fan (1) · Jin Yang, Doctor (1) · Jing Jin, MD, PhD (1) · Jinjun Ye (1) · Jinsong Li, MD, PhD (1) · Jun Huang, PhD. (1) · Jun Ma, MD (1) · Kangshun Zhu, MD (1)
PMID 32781263, PMID 29229461, PMID 29543938, PMID 30119083, PMID 30285222, PMID 30558224, PMID 30612710, PMID 30955977, PMID 31378236, PMID 31402780, PMID 31560378, PMID 32997907, PMID 34048947, PMID 34143971, PMID 34358724, PMID 35440464, PMID 35908558, PMID 35917647, PMID 36336841, PMID 37139963, PMID 37156249, PMID 37464378, PMID 37737025, PMID 38051328, PMID 38353107, PMID 38594905, PMID 38800802, PMID 38824941, PMID 39020518, PMID 39084935, PMID 39267574, PMID 39395411, PMID 39438442, PMID 39884222, PMID 40467307, PMID 40532178, PMID 40651471, PMID 40845854, PMID 40851062, PMID 41629425, PMID 41791006, PMID 42820658